Literature DB >> 27058662

Microbiome and Anticancer Immunosurveillance.

Laurence Zitvogel1, Maha Ayyoub2, Bertrand Routy2, Guido Kroemer3.   

Abstract

Anticancer immune responses can be considered a desirable form of autoimmunity that may be profoundly shaped by the microbiome. Here, we discuss evidence for the microbiome's influence on anti-tumor immunosurveillance, including those that are indirect and can act at a distance, and we put forward hypotheses regarding mechanisms of how these effects are implemented. These may involve cross-reactivity between microbial and tumor antigens shaping T cell repertoires and/or microbial products stimulating pattern recognition receptors that influence the type and intensity of immune responses. Understanding how the microbiome impacts natural cancer immunosurveillance as well as treatment-induced immune responses will pave the way for more effective therapies and prophylactics.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cancer; checkpoint blockers; immunity; immunotherapy; microbiota; pathogen recognition receptors; tumor-associated antigens

Mesh:

Year:  2016        PMID: 27058662     DOI: 10.1016/j.cell.2016.03.001

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  144 in total

1.  SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery.

Authors:  Siwen Hu-Lieskovan; Srabani Bhaumik; Kavita Dhodapkar; Jean-Charles J B Grivel; Sumati Gupta; Brent A Hanks; Sylvia Janetzki; Thomas O Kleen; Yoshinobu Koguchi; Amanda W Lund; Cristina Maccalli; Yolanda D Mahnke; Ruslan D Novosiadly; Senthamil R Selvan; Tasha Sims; Yingdong Zhao; Holden T Maecker
Journal:  J Immunother Cancer       Date:  2020-12       Impact factor: 13.751

Review 2.  Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients.

Authors:  A Mitsuhashi; Y Okuma
Journal:  Clin Transl Oncol       Date:  2018-01-08       Impact factor: 3.405

3.  Pancreatic cancer: Next-generation algorithms for neoantigen selection.

Authors:  Alexander Hopkins; Elizabeth Jaffee
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-01-10       Impact factor: 46.802

Review 4.  A Believer's Overview of Cancer Immunosurveillance and Immunotherapy.

Authors:  Olivera J Finn
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

5.  Assessment of tumor-infiltrating TCRVγ9Vδ2 γδ lymphocyte abundance by deconvolution of human cancers microarrays.

Authors:  Marie Tosolini; Frédéric Pont; Mary Poupot; François Vergez; Marie-Laure Nicolau-Travers; David Vermijlen; Jean-Emmanuel Sarry; Francesco Dieli; Jean-Jacques Fournié
Journal:  Oncoimmunology       Date:  2017-02-06       Impact factor: 8.110

6.  The influence of gut-decontamination prophylactic antibiotics on acute graft-versus-host disease and survival following allogeneic hematopoietic stem cell transplantation.

Authors:  Bertrand Routy; Caroline Letendre; David Enot; Maxime Chénard-Poirier; Vikram Mehraj; Noémie Charbonneau Séguin; Khaled Guenda; Kathia Gagnon; Paul-Louis Woerther; David Ghez; Silvy Lachance
Journal:  Oncoimmunology       Date:  2016-12-27       Impact factor: 8.110

7.  The new identified biomarkers determine sensitivity to immune check-point blockade therapies in melanoma.

Authors:  Hao Chen; Meng Yang; Qinghua Wang; Fengju Song; Xiangchun Li; Kexin Chen
Journal:  Oncoimmunology       Date:  2019-05-10       Impact factor: 8.110

Review 8.  Racial Differences in Cancer Susceptibility and Survival: More Than the Color of the Skin?

Authors:  Berna C Özdemir; Gian-Paolo Dotto
Journal:  Trends Cancer       Date:  2017-03-06

Review 9.  Revisiting the hallmarks of cancer.

Authors:  Yousef Ahmed Fouad; Carmen Aanei
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

Review 10.  Considerations for successful cancer immunotherapy in aged hosts.

Authors:  V Hurez; Á S Padrón; R S Svatek; T J Curiel
Journal:  Clin Exp Immunol       Date:  2016-11-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.